Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
Citations Over TimeTop 10% of 2012 papers
Abstract
E3 ubiquitin ligases, which bind protein targets, leading to their ubiquitination and subsequent degradation, are attractive drug targets due to their exquisite substrate specificity. However, the development of small-molecule inhibitors has proven extraordinarily challenging as modulation of E3 ligase activities requires the targeting of protein-protein interactions. Using rational design, we have generated the first small molecule targeting the von Hippel-Lindau protein (VHL), the substrate recognition subunit of an E3 ligase, and an important target in cancer, chronic anemia, and ischemia. We have also obtained the crystal structure of VHL bound to our most potent inhibitor, confirming that the compound mimics the binding mode of the transcription factor HIF-1α, a substrate of VHL. These results have the potential to guide future development of improved lead compounds as therapeutics for the treatment of chronic anemia and ischemia.
Related Papers
- → Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity(2018)286 cited
- → Identification of the phosphorylation sites on the E3 ubiquitin ligase Pellino that are critical for activation by IRAK1 and IRAK4(2009)75 cited
- → Targeting protein ubiquitylation: DDB1 takes its RING off(2009)14 cited
- A RING-type E3 ubiquitin ligase regulates the transcriptional activity of the clock protein DBP(2019)
- → Faculty Opinions recommendation of Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity.(2018)